All Stories

  1. Global, regional, and national burden of injuries, and burden attributable to injuries risk factors, 1990 to 2019: results from the Global Burden of Disease study 2019
  2. The global, regional, and national burden of urolithiasis in 204 countries and territories, 2000–2021: a systematic analysis for the Global Burden of Disease Study 2021
  3. Global, regional, and national stillbirths at 20 weeks' gestation or longer in 204 countries and territories, 1990–2021: findings from the Global Burden of Disease Study 2021
  4. Association of BMI, lipid-lowering medication, and age with prevalence of type 2 diabetes in adults with heterozygous familial hypercholesterolaemia: a worldwide cross-sectional study
  5. Global, regional, and national burden of stroke and its risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
  6. Forecasting the effects of smoking prevalence scenarios on years of life lost and life expectancy from 2022 to 2050: a systematic analysis for the Global Burden of Disease Study 2021
  7. Heart failure in Europe: Guideline‐directed medical therapy use and decision making in chronic and acute, pre‐existing and de novo, heart failure with reduced, mildly reduced, and preserved ejection fraction – the ESC EORP Heart Failure III Registry
  8. Global, regional, and national burden of upper respiratory infections and otitis media, 1990–2021: a systematic analysis from the Global Burden of Disease Study 2021
  9. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension
  10. European Society of Cardiology: the 2023 Atlas of Cardiovascular Disease Statistics
  11. Global, regional, and national burden of gout, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021
  12. Activity limitations, use of assistive devices, and mortality and clinical events in 25 high-income, middle-income, and low-income countries: an analysis of the PURE study
  13. Prevalence and target attainment of traditional cardiovascular risk factors in patients with systemic lupus erythematosus: a cross-sectional study including 3401 individuals from 24 countries
  14. Global pattern, trend, and cross-country inequality of early musculoskeletal disorders from 1990 to 2019, with projection from 2020 to 2050
  15. Burden of disease scenarios for 204 countries
  16. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
  17. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
  18. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a syst...
  19. Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults
  20. Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
  21. Global fertility in 204 countries and territories, 1950–2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021
  22. Tricuspid regurgitation: Frequency, clinical presentation, management and outcome among patients with severe left‐sided valvular heart disease in Europe. Insights from the ESC‐EORP Valvular Heart Disease II survey
  23. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
  24. Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study
  25. Global Burden of Cardiovascular Diseases and Risks, 1990-2022
  26. Pragmatic solutions to reduce the global burden of stroke: a World Stroke Organization–Lancet Neurology Commission
  27. Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the global burden of disease study 2019
  28. Global burden of peripheral artery disease and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
  29. Global, regional, and national burden of rheumatoid arthritis, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021
  30. Global, regional, and national burden of osteoarthritis, 1990–2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021
  31. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes
  32. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
  33. Association of leptin receptor gene Gln223Arg polymorphism with insulin resistance and hyperglycemia in patients with metabolic syndrome
  34. Global, regional, and national burden of allergic disorders and their risk factors in 204 countries and territories, from 1990 to 2019: A systematic analysis for the Global Burden of Disease Study 2019
  35. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021
  36. Thromboembolic events in peripartum cardiomyopathy: results from the ESC EORP PPCM registry
  37. Hyponatraemia and changes in natraemia during hospitalization for acute heart failure and associations with in‐hospital and long‐term outcomes – from the ESC‐HFA EORP Heart Failure Long‐Term Registry
  38. Global burden of chronic respiratory diseases and risk factors, 1990–2019: an update from the Global Burden of Disease Study 2019
  39. The global Fatty Liver Disease-Sustainable Development Goal country score for 195 countries and territories
  40. Diminishing benefits of urban living for children and adolescents’ growth and development
  41. Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP)
  42. Presentation, care, and outcomes of patients with NSTEMI according to World Bank country income classification: the ACVC-EAPCI EORP NSTEMI Registry of the European Society of Cardiology
  43. Global investments in pandemic preparedness and COVID-19: development assistance and domestic spending on health between 1990 and 2026
  44. Perceived built environment characteristics associated with walking and cycling across 355 communities in 21 countries
  45. The overlapping burden of the three leading causes of disability and death in sub-Saharan African children
  46. Associations of Antibiotics, Hormonal Therapies, Oral Contraceptives, and Long-Term NSAIDS With Inflammatory Bowel Disease: Results From the Prospective Urban Rural Epidemiology (PURE) Study
  47. Care of patients with ST-elevation myocardial infarction: an international analysis of quality indicators in the acute coronary syndrome STEMI Registry of the EURObservational Research Programme and ACVC and EAPCI Associations of the European Society o...
  48. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019
  49. Adherence to the “Atrial fibrillation Better Care” (ABC) pathway in patients with atrial fibrillation and cancer: A report from the ESC-EHRA EURObservational Research Programme in atrial fibrillation (EORP-AF) General Long-Term Registry
  50. Cohort Profile: The ESC EURObservational Research Programme Non-ST-segment elevation myocardial infraction (NSTEMI) Registry
  51. Solid Fuel Use and Health in Developing Countries
  52. Assessing performance of the Healthcare Access and Quality Index, overall and by select age groups, for 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019
  53. Oral anticoagulant treatment in rheumatoid arthritis patients with atrial fibrillation results of an international audit
  54. Clinical complexity and impact of the ABC (Atrial fibrillation Better Care) pathway in patients with atrial fibrillation: a report from the ESC-EHRA EURObservational Research Programme in AF General Long-Term Registry
  55. Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
  56. May Measurement Month 2019: analysis of blood pressure screening in Bishkek, Kyrgyzstan
  57. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
  58. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
  59. Epidemiology and impact of frailty in patients with atrial fibrillation in Europe
  60. Population-level risks of alcohol consumption by amount, geography, age, sex, and year: a systematic analysis for the Global Burden of Disease Study 2020
  61. Estimates, trends, and drivers of the global burden of type 2 diabetes attributable to PM2·5 air pollution, 1990–2019: an analysis of data from the Global Burden of Disease Study 2019
  62. Impact of anthropometric factors on outcomes in atrial fibrillation patients: analysis on 10 220 patients from the European Society of Cardiology (ESC)-European Heart Rhythm Association (EHRA) EurObservational Research Programme on Atrial Fibrillation ...
  63. Impact of chronic coronary syndromes on cardiovascular hospitalization and mortality: the ESC-EORP CICD-LT registry
  64. Adolescent transport and unintentional injuries: a systematic analysis using the Global Burden of Disease Study 2019
  65. Measuring the availability of human resources for health and its relationship to universal health coverage for 204 countries and territories from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019
  66. Impact of malignancy on outcomes in European patients with atrial fibrillation: A report from the ESC‐EHRA EURObservational research programme in atrial fibrillation general long‐term registry
  67. Step‐by‐step diagnosis and management of the nocebo/drucebo effect in statin‐associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP)
  68. Global, regional, and national burden of diseases and injuries for adults 70 years and older: systematic analysis for the Global Burden of Disease 2019 Study
  69. Diabetes mortality and trends before 25 years of age: an analysis of the Global Burden of Disease Study 2019
  70. Variations in the financial impact of the COVID-19 pandemic across 5 continents: A cross-sectional, individual level analysis
  71. Impact of renal impairment on atrial fibrillation: ESC‐EHRA EORP‐AF Long‐Term General Registry
  72. Primary stroke prevention worldwide: translating evidence into action
  73. Clinical utility and prognostic implications of the novel 4S-AF scheme to characterize and evaluate patients with atrial fibrillation: a report from ESC-EHRA EORP-AF Long-Term General Registry
  74. Contemporary Management of Severe Symptomatic Aortic Stenosis
  75. Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
  76. Impact of clinical phenotypes on management and outcomes in European atrial fibrillation patients: a report from the ESC-EHRA EURObservational Research Programme in AF (EORP-AF) General Long-Term Registry
  77. Mapping Anemia in Women: Global Trends and Inequality
  78. Global, regional, and national mortality among young people aged 10–24 years, 1950–2019: a systematic analysis for the Global Burden of Disease Study 2019
  79. Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
  80. Tracking development assistance for health and for COVID-19
  81. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants
  82. Markers of cardiovascular risk and their reversibility with acute oxygen therapy in Kyrgyz highlanders with high altitude pulmonary hypertension
  83. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
  84. Real-world applicability and impact of early rhythm control for European patients with atrial fibrillation: a report from the ESC-EHRA EORP-AF Long-Term General Registry
  85. Hypertensive disorders in women with peripartum cardiomyopathy: insights from the ESC EORP PPCM Registry
  86. Reperfusion therapies and in-hospital outcomes for ST-elevation myocardial infarction in Europe: the ACVC-EAPCI EORP STEMI Registry of the European Society of Cardiology
  87. Measuring routine childhood vaccination coverage in 204 countries and territories
  88. Child Mortality Trends and Targets: GBD 2019 Findings
  89. Potential for optimizing management of obesity in the secondary prevention of coronary heart disease
  90. An international audit of the management of dyslipidaemia and hypertension in patients with rheumatoid arthritis: results from 19 countries
  91. Diabetes mellitus and cardiovascular risk management in patients with rheumatoid arthritis: an international audit
  92. Mapping inequalities in exclusive breastfeeding in low- and middle-income countries, 2000–2018
  93. Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases – A position paper from the International Lipid Expert Panel (ILEP)
  94. Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019
  95. The state of stroke services across the globe: Report of World Stroke Organization–World Health Organization surveys
  96. Spatial, temporal, and demographic patterns in prevalence of chewing tobacco use in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019
  97. Pregnancy outcomes in women with a systemic right ventricle and transposition of the great arteries results from the ESC-EORP Registry of Pregnancy and Cardiac disease (ROPAC)
  98. Glycemic Index, Glycemic Load, and Cardiovascular Disease and Mortality
  99. Burden of Ischemic Heart Disease in Central Asian Countries, 1990–2017
  100. The Heart Failure Association Atlas : Heart Failure Epidemiology and Management Statistics 2019
  101. Heterogeneous contributions of change in population distribution of body mass index to change in obesity and underweight
  102. Gender differences in screening for glucose perturbations, cardiovascular risk factor management and prognosis in patients with dysglycaemia and coronary artery disease: results from the ESC-EORP EUROASPIRE surveys
  103. Pregnancy outcome in thoracic aortic disease data from the Registry Of Pregnancy And Cardiac disease
  104. Pregnancy Outcomes in Women After Arterial Switch Operation for Transposition of the Great Arteries: Results From ROPAC (Registry of Pregnancy and Cardiac Disease) of the European Society of Cardiology EURObservational Research Programme
  105. Peripheral arterial disease and intermittent claudication in coronary heart disease patients
  106. Prediction of recurrent event in patients with coronary heart disease: the EUROASPIRE Risk Model
  107. Mapping routine measles vaccination in low- and middle-income countries
  108. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019
  109. Height and body-mass index trajectories of school-aged children and adolescents from 1985 to 2019 in 200 countries and territories: a pooled analysis of 2181 population-based studies with 65 million participants
  110. Alcohol consumption patterns across Europe and adherence to the European guidelines in coronary patients: Findings from the ESC-EORP EUROASPIRE V survey
  111. Relation of outcomes to ABC (Atrial Fibrillation Better Care) pathway adherent care in European patients with atrial fibrillation: an analysis from the ESC-EHRA EORP Atrial Fibrillation General Long-Term (AFGen LT) Registry
  112. Five insights from the Global Burden of Disease Study 2019
  113. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019
  114. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
  115. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
  116. Mapping geographical inequalities in access to drinking water and sanitation facilities in low-income and middle-income countries, 2000–17
  117. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease
  118. Estimating global injuries morbidity and mortality: methods and data used in the Global Burden of Disease 2017 study
  119. Acute Coronary Syndrome and Ischemic Heart Disease in Pregnancy: Data From the EURObservational Research Programme‐European Society of Cardiology Registry of Pregnancy and Cardiac Disease
  120. Mapping geographical inequalities in oral rehydration therapy coverage in low-income and middle-income countries, 2000–17
  121. Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
  122. May Measurement Month 2019
  123. Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis
  124. Author Correction: Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017
  125. Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000–17: analysis for the Global Burden of Disease Study 2017
  126. Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
  127. Department of Error
  128. Repositioning of the global epicentre of non-optimal cholesterol
  129. Global, Regional, and National Burden of Calcific Aortic Valve and Degenerative Mitral Valve Diseases, 1990–2017
  130. Statin therapy in athletes and patients performing regular intense exercise – Position paper from the International Lipid Expert Panel (ILEP)
  131. The impact of type of dietary protein, animal versus vegetable, in modifying cardiometabolic risk factors: A position paper from the International Lipid Expert Panel (ILEP)
  132. The Kyrgyz Society of Cardiology
  133. Global injury morbidity and mortality from 1990 to 2017: results from the Global Burden of Disease Study 2017
  134. Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017
  135. Unravelling the interplay between hyperkalaemia, renin–angiotensin–aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC‐HFA‐EORP Heart Failure Long‐Term Registry
  136. Health sector spending and spending on HIV/AIDS, tuberculosis, and malaria, and development assistance for health: progress towards Sustainable Development Goal 3
  137. Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC‐EORP Heart Failure Long‐Term Registry
  138. Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries
  139. The Heart Failure Association Atlas: rationale, objectives, and methods
  140. The global, regional, and national burden of gastro-oesophageal reflux disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
  141. Coronary patients and diabetes in Europe
  142. GBD 2016. Occupational Carcinogens Collaborators
  143. Global and regional burden of chronic respiratory disease in 2016 arising from non-infectious airborne occupational exposures: a systematic analysis for the Global Burden of Disease Study 2016
  144. Global and regional burden of disease and injury in 2016 arising from occupational exposures: a systematic analysis for the Global Burden of Disease Study 2016
  145. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
  146. ‘Medicine of the Silk Road’
  147. The global burden of falls: global, regional and national estimates of morbidity and mortality from the Global Burden of Disease Study 2017
  148. Burden of injury along the development spectrum: associations between the Socio-demographic Index and disability-adjusted life year estimates from the Global Burden of Disease Study 2017
  149. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
  150. Mapping child growth failure across low- and middle-income countries
  151. Quantifying risks and interventions that have affected the burden of diarrhoea among children younger than 5 years: an analysis of the Global Burden of Disease Study 2017
  152. Quantifying risks and interventions that have affected the burden of lower respiratory infections among children younger than 5 years: an analysis for the Global Burden of Disease Study 2017
  153. The prevalence of major cardiovascular risk factors in rural population of the Chui region of Kyrgyzstan: results of an epidemiological study
  154. The Joint Scientific Symposium with the European Atherosclerosis Society (EAS), the International Atherosclerosis Society (IAS) and the Kyrgyz Society of Cardiology (KSC) in the frame of the International Symposium “Medicine of the Silk Road”
  155. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
  156. Tension Hemothorax Secondary to Percutaneous Dilational Tracheostomy Tube Placement
  157. Comparisons of microbiota-generated metabolites in patients with young and elderly acute coronary syndrome
  158. Mapping disparities in education across low- and middle-income countries
  159. European Society of Cardiology: Cardiovascular Disease Statistics 2019
  160. Cohort profile The ESC-EORP Chronic Ischemic Cardiovascular Disease Long-Term (CICD LT) registry
  161. Mapping 123 million neonatal, infant and child deaths between 2000 and 2017
  162. Contemporary Presentation and Management of Valvular Heart Disease
  163. Pulmonary Coccidioidomycosis Diagnosed by Endobronchial Ultrasound With Fine Needle Aspiration Biopsy of a Paratracheal Pulmonary Nodule
  164. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes
  165. Kyrgyz Society of Cardiology Annual Congress 2019
  166. THE ESC ACCA EAPCI EORP Acute Coronary Syndrome ST elevation myocardial infarction (ACS STEMI) REGISTRY
  167. Past, present, and future of global health financing: a review of development assistance, government, out-of-pocket, and other private spending on health for 195 countries, 1995–2050
  168. Department of Error
  169. Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries
  170. Is chest radiography routinely needed after thoracentesis?
  171. Rising rural body-mass index is the main driver of the global obesity epidemic in adults
  172. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
  173. A woman, age 35, with new-onset ascites
  174. Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
  175. The frequency of familial hypercholesterolemia amongst patients in the outpatient clinic of the tertiary specialized cardiology center in Kyrgyzstan
  176. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry
  177. Global, regional, and national burden of suicide mortality 1990 to 2016: systematic analysis for the Global Burden of Disease Study 2016
  178. The Silk Road Symposium 2018
  179. Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
  180. Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017
  181. OUP accepted manuscript
  182. A familial hypercholesterolemia week in Kyrgyzstan: The joint scientific and practical symposium with the European Atherosclerosis Society (EAS), the International Atherosclerosis Society (IAS) and the Kyrgyz Society of Cardiology (KSC)
  183. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017
  184. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease ...
  185. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
  186. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
  187. Measuring progress of the health-related Sustainable Development Goals for 195 countries
  188. Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017
  189. Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017
  190. Department of Error
  191. Association between the intima-media thickness of the extracranial carotid arteries and metabolic syndrome in ethnic Kyrgyzs
  192. The Role of the European Society of Cardiology in improving the quality of cardiac care at the level of national cardiac societies
  193. Gene-gene interactions and the contribution of polymorphic loci of the KCNJ11, ADIPOQ, omentin, leptin, TCF7L2 and PPARg genes to the development of type 2 diabetes mellitus in the Kyrgyz population: a case-control genetic association study using MDR a...
  194. Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
  195. Reduced Introgression of Sex Chromosome Markers in the Mexican Howler Monkey (Alouatta palliata × A. pigra) Hybrid Zone
  196. Alcohol use and attributable disease burden in 195
  197. When does S aureus bacteremia require transesophageal echocardiography?
  198. Measuring performance_Healthcare Access_Quality Index for 195 countries and territories
  199. An Association of Cardiovascular Risk Factors with T1264G of CD 36 Gene Polymorphism in Kyrgyz Population
  200. Spending on health and HIV/AIDS: domestic health spending and development assistance in 188 countries, 1995–2015
  201. Trends in future health financing and coverage: future health spending and universal health coverage in 188 countries, 2016–40
  202. The Burden of Cardiovascular Diseases Among US States, 1990-2016
  203. The scientific and educational activity of the European Atherosclerosis Society (EAS) in Kyrgyzstan
  204. 2018 ESC Guidelines for the diagnosis and management of syncope
  205. Contributions of mean and shape of blood pressure distribution to worldwide trends and variations in raised blood pressure: a pooled analysis of 1018 population-based measurement studies with 88.6 million participants
  206. The association of Val109Asp polymorphic marker of intelectin 1 gene with abdominal obesity in Kyrgyz population
  207. Recurrent migration of peripherally inserted central catheter into the azygos vein
  208. “Medicine of the Silk Road”
  209. Near and Far
  210. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults
  211. The Kyrgyzstan Cardiology Congress, 2017
  212. Department of Error
  213. Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry
  214. Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016
  215. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016
  216. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
  217. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
  218. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
  219. Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease Study 2016
  220. Department of Error
  221. What Can Be Done to Maintain Positive Patient Experience and Improve Residents' Satisfaction? In Reference to: “Standardized Attending Rounds to Improve the Patient Experience: A Pragmatic Cluster Randomized Controlled Trial”
  222. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
  223. Burden of cardiovascular diseases in the Eastern Mediterranean Region, 1990–2015: findings from the Global Burden of Disease 2015 study
  224. Health Effects of Overweight and Obesity in 195 Countries over 25 Years
  225. Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015
  226. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015
  227. Evolution and patterns of global health financing 1995–2014: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries
  228. Future and potential spending on health 2015–40: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries
  229. Wake-Up Call: Pulmonary Arteriovenous Malformation
  230. 2016 ESC GUIDELINES FOR THE MANAGEMENT OF ATRIAL FIBRILLATION DEVELOPEDIN COLLABORATION WITH EACTS
  231. The Role of Sodium Bicarbonate in the Management of Some Toxic Ingestions
  232. Ring-enhancing cerebral lesions
  233. When should brain imaging precede lumbar puncture in cases of suspected bacterial meningitis?
  234. Association between sleep apnoea and pulmonary hypertension in Kyrgyz highlanders
  235. Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration
  236. DRESS Syndrome Following Metformin Administration: A Case Report and Review of the Literature
  237. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015
  238. Dexamethasone reduces pulmonary artery pressure in lowlanders with COPD travelling to 3200m. A randomized, placebo-controlled trial: TABLE 1
  239. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
  240. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
  241. Indwelling Tunneled Pleural Catheters for the Management of Hepatic Hydrothorax: A Word of Caution
  242. Management of Hyperkalemia: Put It into Context
  243. Video Laryngoscopy: Take It to the Floor
  244. Wilson disease (February 2016)
  245. Leukostasis in adult acute hyperleukocytic leukemia: a clinician's digest
  246. An Emotional Stress as a Trigger for Reverse Takotsubo Cardiomyopathy: A Case Report and Literature Review
  247. In reference to “as‐needed intravenous antihypertensive therapy and blood pressure control”
  248. High-altitude Pulmonary Hypertension: an Update on Disease Pathogenesis and Management
  249. Association between Serum IGF-I levels and Postoperative Delirium in Elderly Subjects Undergoing Elective Knee Arthroplasty
  250. The Role of Renal Replacement Therapy in the Management of Pharmacologic Poisonings
  251. Risk of malignant arrhythmia in highlanders with high altitude pulmonary hypertension during wakefulness and sleep
  252. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death
  253. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases
  254. Cerebral oxygenation in highlanders with and without high-altitude pulmonary hypertension
  255. Association Between T455C Polymorphism of Apolipoprotein C-III Gene, Insulin Resistance and Metabolic Syndrome Components
  256. Intravenous Contrast Material and Acute Kidney Injury: A Need for Caution
  257. AB1078 Diagnostic Value of Serological Markers in Rheumatoid Arthritis in Patients of Kyrgyz Republic
  258. Alcoholic hepatitis: An important consideration (April 2015)
  259. Antisynthetase Syndrome: A Review of Etiopathogenesis, Diagnosis and Management
  260. Hypercalcemia of malignancy: An update on pathogenesis and management
  261. Case Report of a Patient with Left Ventricular Assistance Device Undergoing Chemotherapy for a New Diagnosis of Lung Cancer
  262. Propofol Infusion Syndrome in Adults: A Clinical Update
  263. Clostridium perfringens Bacteremia in an 85-Year-Old Diabetic Man
  264. Airway Training for Critical Care Fellows: More Than Just Video Laryngoscopy
  265. CardioPulse ArticlesThe 2014 ESC Guidelines on the Diagnosis and Management of Hypertrophic Cardiomyopathy have been publishedThe ‘Ten Commandments’ of the ESC Hypertrophic Cardiomyopathy GuidelinesEuroPCR 2014, Hypertension and Heart Failure Track tak...
  266. 2014 ESC/ESA Guidelines on non-cardiac surgery
  267. Overtesting: A Sign of Defective Medicine
  268. 2014 ESC/EACTS Guidelines on myocardial revascularization
  269. CardioPulse Articles
  270. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management
  271. Sleep Apnea and Ectopic Fat Deposition
  272. Tumor Lysis Syndrome in Solid Tumors: An up to Date Review of the Literature
  273. Obstructive Sleep Apnea and Preclinical Cardiac Damage: Need for U.S. Representative Study Sample
  274. Primary Anorectal Melanoma
  275. Primary Antiphospholipid Syndrome and Pulmonary Hypertension
  276. Rhabdomyolysis
  277. Postsurgical pneumoencephaly in a patient with Klippel-Feil syndrome
  278. Prevalence of health risk behaviors and their associated factors among university students in Kyrgyzstan
  279. Lipids and leptin level in natives of Kyrgyzstan
  280. The association of leptin with dyslipidemia, arterial hypertension and obesity in Kyrgyz (Central Asian nation) population
  281. Nonalcoholic fatty pancreatic disease and cardio-metabolic risk: is there is a place for obstructive sleep apnea?
  282. Primary Nephrotic Syndrome in Adults as a Risk Factor for Pulmonary Embolism: An Up-to-Date Review of the Literature
  283. Primary Small Cell Neuroendocrine Carcinoma of Paranasal Sinuses
  284. Systemic Tentacles of Chronic Obstructive Pulmonary Disease: Do We Need to Account for Renal Damage?
  285. Obstructive sleep apnoea, gout and cardiovascular risk: A worth studying association
  286. Propofol and the risk of delirium: Exploring the anticholinergic properties of propofol
  287. Obstructive Sleep Apnea and Autoimmune Rheumatic Disease: Is there Any Link?
  288. Types of Sleep Apnea in Patients With Heart Failure
  289. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: Is There a Place for Obstructive Sleep Apnea?
  290. Sleep disordered breathing and cardiovascular disease: Another brick in the wall
  291. Ortner's syndrome: a rare cause of hoarseness
  292. High-sensitivity cardiac troponin in patients with stable chronic obstructive pulmonary disease: looking beyond the lungs
  293. An uncommon cause of haemoptysis in a 69-year-old women
  294. Obstructive Sleep Apnea and Sodium Intake
  295. Reply: Characterization of Lymphangioleiomyomatosis as a Neoplastic Disease
  296. Delirium after cardiac surgery: Have we overlooked obstructive sleep apnea?
  297. Primary Diffuse Large B-Cell Lymphoma of the Ascending Colon
  298. Cholangiocarcinoma and brain lesions: an extremely rare finding
  299. Mediastinal involvement in ovarian cancer
  300. Eosinophilic pneumonia associated with concomitant cigarette and marijuana smoking
  301. Chronic Obstructive Pulmonary Disease and Vascular Risk: Should We Account for Diabetes Mellitus and Renal Disease?
  302. Prostate adenocarcinoma with a rectal metastasis
  303. Physician Burnout: An Urgent Call for Early Intervention
  304. A case of colovesical fistula caused by the eroded rectal stent
  305. Brain metastasis from oesophageal adenocarcinoma
  306. Obstructive Sleep Apnea and Autoimmune Disease: A Two-Way Process
  307. Obstructive sleep apnea and delirium: exploring possible mechanisms
  308. Septic shock caused by Elizabethkingia meningoseptica: a case report and review of literature
  309. A rare cause of superior vena cava syndrome
  310. Comment on: Obstructive sleep apnoea in relation to rheumatic disease
  311. Non-healing pharyngeal ulcer in a middle-aged Caucasian man
  312. Obstructive sleep apnea: Looking at the whole picture
  313. Frequency of C825T G protein β3 subunit gene polymorphism and its association with obesity in the Kyrgyz population
  314. Prevalence of obstructive sleep apnea in Asian adults: a systematic review of the literature
  315. New pulmonary nodules in a patient with rheumatoid arthritis
  316. Physical exercise related improvement in obstructive sleep apnea. Look for the rostral fluid shift
  317. Metastatic adenocarcinoma of the colon in a 21-year-old African-American woman
  318. Monoclonal gammopathy of undetermined significance associated with blue finger syndrome
  319. Response to Independent Association Between Obstructive Sleep Apnea and Noncalcified Coronary Plaque Demonstrated by Noninvasive Coronary Computed Tomography Angiography
  320. Obstructive sleep apnea and dyslipidemia: importance of the liver axis
  321. Supine fluid redistribution: should we consider this as an important risk factor for obstructive sleep apnea?
  322. Remembering: Academician Mirsaid Mirrakhimov (1927-2008)
  323. Cut off values for abdominal obesity as a criterion of metabolic syndrome in an ethnic Kyrgyz population (Central Asian region)
  324. Influence of one-year treatment with lovastatin on myocardial remodeling and ischemia in patients with coronary artery disease
  325. An association between TRP64ARG polymorphism of the B3 adrenoreceptor gene and some metabolic disturbances
  326. Rheumatologic services in Central Asian countries: current state of development of rheumatology in Central Asia
  327. The effects of 12-month lovastatin therapy on carotid atherosclerosis in patients with hyperlipidemia
  328. Evaluation of the economic efficiency of educational programs for patients with coronary heart disease and dyslipidemia
  329. Silent ischemia and prognosis after acute myocardial infarction